<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959166</url>
  </required_header>
  <id_info>
    <org_study_id>09/H0712/17</org_study_id>
    <nct_id>NCT00959166</nct_id>
  </id_info>
  <brief_title>To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection</brief_title>
  <official_title>A Prospective Case-control Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-infection - a PET Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to evaluate what happens to the brain in patients with HIV and early
      hepatitis C. The investigators will be comparing 3 groups of individuals:

        -  Group 1: Individuals with HIV infection and acute (early) hepatitis C infection

        -  Group 2: Individuals with HIV infection

        -  Group 3: Healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subtle changes to the brain, which doctors find difficult to detect through conversation or
      examination, may occur in patients with HIV and/or hepatitis C infection. It is not currently
      known whether the brain is affected in early (or acute) hepatitis C.

      Individuals wishing to take part will complete a series of tests assessing different aspects
      of their brain including:

        -  2 brain scans using different technology:

             -  Magnetic resonance imaging (MRI) brain scan with spectroscopy

             -  CT PET brain scan

        -  A computer game test which measures brain function

        -  2 short questionnaires

      Results of these tests will be analyzed and compared between 3 groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Association of 11C-labelled PK11195 Uptake Using PET With Acute HCV and HIV Infection</measure>
    <time_frame>30 days</time_frame>
    <description>Association of 11C-labelled PK11195 uptake using PET with acute HCV and HIV infection by PK11195 PET ligand binding. The ligand PK11195 is selective for the peripheral benzodiazepine binding site and exhibits minimal binding in normal brain. In brain lesions, however, there is a massive increase in binding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of NAA/Cr (N-acetyl Aspartate/Creatine) Cerebral Metabolites</measure>
    <time_frame>30 days</time_frame>
    <description>Association between patient characteristics and 11C-labelled PK11195 uptake using PET, CNS metabolite ratios.
By quantifying the surrogate markers of N-acetylaspartate (NAA), creatine (Cr) offers insight into the neuronal integrity, cell membrane synthesis and turnover, macrophage infiltration, inflammation status, and levels of microglial activation and gliosis within the sampled CNS tissue.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Acute Hepatitis C</condition>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV/acute HCV coinfection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV mono</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HIV-infected individuals without hepatitis C co-infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <description>PET brain scan</description>
    <arm_group_label>HIV mono</arm_group_label>
    <arm_group_label>HIV/acute HCV coinfection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 antibody positive for at least 12 months

          2. Acute HCV (Blood HCV PCR positive with negative PCR within past 8 months)

          3. HCV genotype 1

          4. Ability to give informed consent

          5. Aged &gt; 25 years

          6. Male

          7. Abbreviated Mental Test Score of at least 8/10

        Exclusion Criteria:

          1. Evidence of established cirrhosis or encephalopathy

          2. Commencing or any change to HIV medications within 12 weeks

          3. Active opportunistic infection

          4. Taking anti-depressants or any psychoactive medications within past 4 weeks

          5. Use of benzodiazepines within past 4 weeks

          6. Recent significant head injury

          7. Established dementia

          8. Alcohol dependence or recreational drug misuse

          9. Untreated early syphilis

         10. Hepatitis B infection (HBsAg positive)

         11. Pregnancy

         12. Unable to give informed consent

         13. Any contraindication to MR scanning
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Winston</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Garvey LJ, Pavese N, Ramlackhansingh A, Thomson E, Allsop JM, Politis M, Kulasegaram R, Main J, Brooks DJ, Taylor-Robinson SD, Winston A. Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. PLoS One. 2012;7(7):e38980. doi: 10.1371/journal.pone.0038980. Epub 2012 Jul 12.</citation>
    <PMID>22808022</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>October 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2019</results_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute hepatitis C</keyword>
  <keyword>HIV</keyword>
  <keyword>Neurocognitive function</keyword>
  <keyword>Neuroinflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV/Acute HCV Coinfection</title>
          <description>Subjects with HIV/acute HCV coinfection</description>
        </group>
        <group group_id="P2">
          <title>HIV Mono</title>
          <description>HIV-infected individuals without hepatitis C co-infection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV/Acute HCV Coinfection</title>
          <description>Subjects with HIV/acute HCV coinfection</description>
        </group>
        <group group_id="B2">
          <title>HIV Mono</title>
          <description>HIV-infected individuals without hepatitis C co-infection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="36" upper_limit="44"/>
                    <measurement group_id="B2" value="47" lower_limit="39" upper_limit="56"/>
                    <measurement group_id="B3" value="44" lower_limit="36" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time-elapsed since HIV diagnosis</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="B2" value="11" lower_limit="5" upper_limit="16"/>
                    <measurement group_id="B3" value="8.5" lower_limit="3" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current CD4+ cells</title>
          <units>cells/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="590" lower_limit="458" upper_limit="745"/>
                    <measurement group_id="B2" value="505" lower_limit="382" upper_limit="783"/>
                    <measurement group_id="B3" value="547" lower_limit="382" upper_limit="783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants receiving antiretroviral therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV viral load below 50c/ml</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Association of 11C-labelled PK11195 Uptake Using PET With Acute HCV and HIV Infection</title>
        <description>Association of 11C-labelled PK11195 uptake using PET with acute HCV and HIV infection by PK11195 PET ligand binding. The ligand PK11195 is selective for the peripheral benzodiazepine binding site and exhibits minimal binding in normal brain. In brain lesions, however, there is a massive increase in binding.</description>
        <time_frame>30 days</time_frame>
        <population>16 subjects in total had PET scans and were included in the PET outcome</population>
        <group_list>
          <group group_id="O1">
            <title>HIV/Acute HCV Coinfection</title>
            <description>Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.</description>
          </group>
          <group group_id="O2">
            <title>HIV Mono</title>
            <description>HIV-infected individuals without hepatitis C co-infection</description>
          </group>
        </group_list>
        <measure>
          <title>Association of 11C-labelled PK11195 Uptake Using PET With Acute HCV and HIV Infection</title>
          <description>Association of 11C-labelled PK11195 uptake using PET with acute HCV and HIV infection by PK11195 PET ligand binding. The ligand PK11195 is selective for the peripheral benzodiazepine binding site and exhibits minimal binding in normal brain. In brain lesions, however, there is a massive increase in binding.</description>
          <population>16 subjects in total had PET scans and were included in the PET outcome</population>
          <units>binding potential ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.10"/>
                    <measurement group_id="O2" value="0.22" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of NAA/Cr (N-acetyl Aspartate/Creatine) Cerebral Metabolites</title>
        <description>Association between patient characteristics and 11C-labelled PK11195 uptake using PET, CNS metabolite ratios.
By quantifying the surrogate markers of N-acetylaspartate (NAA), creatine (Cr) offers insight into the neuronal integrity, cell membrane synthesis and turnover, macrophage infiltration, inflammation status, and levels of microglial activation and gliosis within the sampled CNS tissue.</description>
        <time_frame>30 days</time_frame>
        <population>24/12 subjects in each study group had MR spectroscopy and could be included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>HIV/Acute HCV Coinfection</title>
            <description>Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.</description>
          </group>
          <group group_id="O2">
            <title>HIV Mono</title>
            <description>HIV-infected individuals without hepatitis C co-infection</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of NAA/Cr (N-acetyl Aspartate/Creatine) Cerebral Metabolites</title>
          <description>Association between patient characteristics and 11C-labelled PK11195 uptake using PET, CNS metabolite ratios.
By quantifying the surrogate markers of N-acetylaspartate (NAA), creatine (Cr) offers insight into the neuronal integrity, cell membrane synthesis and turnover, macrophage infiltration, inflammation status, and levels of microglial activation and gliosis within the sampled CNS tissue.</description>
          <population>24/12 subjects in each study group had MR spectroscopy and could be included in this analysis</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.25"/>
                    <measurement group_id="O2" value="1.35" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HIV/Acute HCV Coinfection</title>
          <description>Subjects with HIV/acute HCV coinfection</description>
        </group>
        <group group_id="E2">
          <title>HIV Mono</title>
          <description>HIV-infected individuals without hepatitis C co-infection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Alan Winston</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 3312 1603</phone>
      <email>a.winston@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

